

Title (en)
Novel parenteral carbamazepine formulation

Title (de)
Neuartige parenterale Carbamazepinformulierung

Title (fr)
Nouvelle formulation parentérale de carbamazépine

Publication
EP 2444090 A1 20120425 (EN)

Application
EP 12150783 A 20061002

Priority
• US 72269205 P 20050930
• EP 06816054 A 20061002
• US 2006038508 W 20061002

Abstract (en)
The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Patent Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.

IPC 8 full level
A61K 31/55 (2006.01)

CPC (source: EP US)
A61K 9/0019 (2013.01 - US); **A61K 31/55** (2013.01 - EP US); **A61K 31/724** (2013.01 - EP US); **A61K 47/40** (2013.01 - US); **A61K 47/6951** (2017.08 - EP US); **A61P 9/00** (2018.01 - EP); **A61P 9/08** (2018.01 - EP); **A61P 21/02** (2018.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 25/08** (2018.01 - EP); **B82Y 5/00** (2013.01 - EP US); **C08B 37/0012** (2013.01 - US); **C08B 37/0015** (2013.01 - EP US)

C-Set (source: EP US)
1. **A61K 31/55 + A61K 2300/00**
2. **A61K 31/724 + A61K 2300/00**

Citation (applicant)
• US 5231089 A 19930727 - BODOR NICHOLAS S [US]
• US 3459731 A 19690805 - GRAMERA ROBERT E, et al
• US 5134127 A 19920728 - STELLA VALENTINO [US], et al
• US 5376645 A 19941227 - STELLA VALENTINO J [US], et al
• SPINA E: "Antiepileptic Drugs", 2002, LIPPINCOTT, WILLIAMS & WILKINS, pages: 236 - 246
• J. SZEJTLI, CYCLODEXTRINS IN DRUG FORMULATIONS: PART II, PHARMACEUTICAL TECHNOLOGY, 24 August 1991 (1991-08-24)
• "Guidance for Industry", January 2001, FOOD AND DRUG ADMINISTRATIONS, article "Statistical Approaches to Establishing Bioequivalence"
• OSTERLOH J; BERTILSSON L: "The absence of isotopic effect during the elimination of deuterium labeled carbamazepine in the rat", LIFE SCI., vol. 23, 1978, pages 83 - 7, XP023737745, DOI: doi:10.1016/0024-3205(78)90330-2
• SINZ MW; REMMEL RP: "Analysis of lamotrigine and lamotrigine 2-N-glucuronide in guinea pig blood and urine by reserved- phase ion-pairing liquid chromatography", J CHROMATOGR., vol. 571, 1991, pages 217 - 30
• CRIT. REV. THER. DRUG CARRIER SYSTEMS, vol. 14, no. 1, 1997, pages 1 - 104
• STELLA ET AL.: "simulated drug release from cyclodextrins upon dilution", ADVANCED DRUG DEL. REV., vol. 36, 1999, pages 3 - 16
• J. PHARM. SCI., vol. 90, 1990, pages 1106 - 1114

Citation (search report)
• [XY] WO 9517191 A1 19950629 - COMMISSARIAT ENERGIE ATOMIQUE [FR], et al
• [XY] US 5231089 A 19930727 - BODOR NICHOLAS S [US]
• [X] WO 03043602 A1 20030530 - DDS TECH CO LTD [KR], et al
• [X] US 6046177 A 20000404 - STELLA VALENTINO J [US], et al
• [A] WO 9111172 A1 19910808 - UNIV KANSAS [US]
• [X] SMITH J S ET AL: "Effect of SBE7-beta-cyclodextrin complexation on carbamazepine release from sustained release beads.", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS : OFFICIAL JOURNAL OF ARBEITSGEMEINSCHAFT FÜR PHARMAZEUTISCHE VERFAHRENSTECHNIK E.V MAY 2005, vol. 60, no. 1, May 2005 (2005-05-01), pages 73 - 80, XP002543594, ISSN: 0939-6411

Citation (third parties)
Third party : Richard Cooke
• WO 9517191 A1 19950629 - COMMISSARIAT ENERGIE ATOMIQUE [FR], et al
• US 5231089 A 19930727 - BODOR NICHOLAS S [US]
• WO 03043602 A1 20030530 - DDS TECH CO LTD [KR], et al
• US 6046177 A 20000404 - STELLA VALENTINO J [US], et al
• WO 9111172 A1 19910808 - UNIV KANSAS [US]
• US 6546131 B1 20030408 - MIZOGUCHI YOSHITO [JP], et al
• US 6458770 B1 20021001 - VAN HOOGEVEST PETER [CH]
• US 2004157796 A1 20040812 - GOKARN YATIN [US]
• US 6218375 B1 20010417 - RAGHAVAN KRISHNASWAMY S [US], et al
• AU 1320095 A 19950710 - COMMISSARIAT ENERGIE ATOMIQUE
• US 5376645 A 19941227 - STELLA VALENTINO J [US], et al
• US 5134127 A 19920728 - STELLA VALENTINO [US], et al
• SMITH J S ET AL: "Effect of SBE7-beta-cyclodextrin complexation on carbamazepine release from sustained release beads.", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 60, no. 1, 1 May 2005 (2005-05-01), pages 73 - 80, XP002543594, ISSN: 0939-6411
• UEDA H ET AL.: "Evaluation of a Sulfobutyl Ether beta-Cyclodextrin as a Solubilizing/Stabilizing Agent for Several Drugs", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 24, no. 9, September 1998 (1998-09-01), pages 863 - 867, XP009040590

- WOLFGANG LÖSCHER , DAGMAR HÖNACK: "Intravenous carbamazepine: comparison of different parenteral formulations in a mouse model of convulsive status epilepticus", EPILEPSIA, vol. 38, no. 1, January 1997 (1997-01-01), pages 106 - 113, XP055428280
- BREWSTER M E; ET AL: "Development of aqueous parenteral formulations for carbamazepine through the use of modified cyclodextrins", JOURNAL OF PHARMACEUTICAL SCIENCES,, vol. 80, no. 4, April 1991 (1991-04-01), pages 380 - 383, XP000200541
- WOLFGANG LOSCHER, ET AL.: "New Injectable Aqueous Carbamazepine Solution Through Complexing with 2-Hydroxypropyl-beta-Cyclodextrin: Tolerability and Pharmacokinetics After Intravenous Injection in Comparison to a Glycofurol-Based Formulation", EPILEPSIA, vol. 36, no. 3, March 1995 (1995-03-01), pages 255 - 261, XP055428288
- RAJEWSKI ET AL.: "Preliminary safety evaluation of parenterally administered sulfoalkyl ether beta-cyclodextrin derivatives", JOURNAL OF PHARMACEUTICAL SCIENCES,, vol. 84, no. 8, August 1995 (1995-08-01), pages 927 - 932, XP000517190
- ANONYMOUS: "BNF 49 /British National Formulary/", March 2005, BRITISH MEDICAL ASSOCIATION AND ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN, ISBN: 978-0-85369-631-5, ISSN: 0260-535X, article "5.2 Antifungal drugs", pages: 2pp, 309, XP055428274

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK RS

DOCDB simple family (publication)

WO 2007041524 A2 20070412; WO 2007041524 A3 20070913; AU 2006299501 A1 20070412; AU 2006299501 A2 20080508; AU 2006299501 B2 20121129; BR PI0616447 A2 20110621; CA 2624463 A1 20070412; CA 2624463 C 20170214; CN 101309691 A 20081119; CY 1115517 T1 20170104; DK 1928464 T3 20140623; EP 1928464 A2 20080611; EP 1928464 A4 20091021; EP 1928464 B1 20140514; EP 2444090 A1 20120425; EP 2444090 B1 20181212; ES 2475157 T3 20140710; ES 2708375 T3 20190409; JP 2009510123 A 20090312; JP 2013040195 A 20130228; JP 5284096 B2 20130911; JP 5794966 B2 20151014; MX 2008004287 A 20081023; NZ 567290 A 20110826; PL 1928464 T3 20141031; PT 1928464 E 20140710; RU 2008117161 A 20091110; RU 2012112839 A 20131010; RU 2455996 C2 20120720; SI 1928464 T1 20140930; US 2007185054 A1 20070809; US 2022265547 A1 20220825; US 2024165125 A1 20240523; ZA 200803332 B 20110525

DOCDB simple family (application)

US 2006038508 W 20061002; AU 2006299501 A 20061002; BR PI0616447 A 20061002; CA 2624463 A 20061002; CN 200680042810 A 20061002; CY 141100467 T 20140626; DK 06816054 T 20061002; EP 06816054 A 20061002; EP 12150783 A 20061002; ES 06816054 T 20061002; ES 12150783 T 20061002; JP 2008533754 A 20061002; JP 2012230330 A 20121017; MX 2008004287 A 20061002; NZ 56729006 A 20061002; PL 06816054 T 20061002; PT 06816054 T 20061002; RU 2008117161 A 20061002; RU 2012112839 A 20120402; SI 200631794 T 20061002; US 202117501287 A 20211014; US 202318336419 A 20230616; US 54252006 A 20061002; ZA 200803332 A 20080415